Walsh Susan M, Fisher Susan G, Sage Ronald A
Department of Orthopedic Surgery and Rehabilitation, Stritch School of Medicine, Loyola University Medical Center, Maywood, IL, USA.
J Foot Ankle Surg. 2003 Jul-Aug;42(4):193-8. doi: 10.1016/s1067-2516(03)70028-3.
Malignant melanoma is increasing at a rate faster than any other cancer in the United States. Location of the primary tumor on the foot is associated with poorer prognosis. This study evaluates a cohort of 148 patients with melanoma of the lower extremity (37 foot or ankle and 111 leg, knee, or thigh) diagnosed at a university medical center during a 32-year period. The mean follow-up for the foot/ankle patients was 44 months. The overall 5-year survival rate was 52% for patients with a primary melanoma of the foot/ankle compared with 84% for patients with a primary melanoma elsewhere on the lower extremity. Although the study period extended over 32 years, nearly 65% of the foot/ankle patients were diagnosed in the last decade. This increase is most likely because of the documented increase in incidence of melanoma in the United States and an increasing referral pattern at our institution.
